TD Cowen Has Lowered Expectations for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its price target lowered by equities researchers at TD Cowen from $25.00 to $23.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. TD Cowen’s target price indicates a potential upside of 18.40% from the stock’s previous close.

Several other analysts have also recently commented on HIMS. BTIG Research cut Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Barclays increased their price target on Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 11th. Evercore set a $24.00 price target on Hims & Hers Health in a report on Tuesday, February 24th. Finally, Citigroup raised shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and raised their target price for the company from $13.25 to $24.00 in a research note on Tuesday, March 10th. Three investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $31.71.

Hims & Hers Health Trading Down 6.9%

Shares of NYSE HIMS opened at $19.43 on Friday. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. The company has a market cap of $4.43 billion, a price-to-earnings ratio of 38.09, a price-to-earnings-growth ratio of 2.34 and a beta of 2.55. Hims & Hers Health has a 12-month low of $13.74 and a 12-month high of $70.43. The stock’s 50 day simple moving average is $21.73 and its 200 day simple moving average is $35.78.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. During the same quarter last year, the company earned $0.11 EPS. The company’s revenue for the quarter was up 28.4% compared to the same quarter last year. Equities research analysts expect that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 4,812 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $118,808.28. Following the completion of the transaction, the insider directly owned 308,831 shares in the company, valued at $7,625,037.39. This trade represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Irene Becklund sold 5,529 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $136,511.01. Following the completion of the transaction, the insider directly owned 8,752 shares in the company, valued at approximately $216,086.88. This trade represents a 38.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 134,984 shares of company stock worth $3,458,041. Company insiders own 13.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently made changes to their positions in the company. Hsbc Holdings PLC grew its position in Hims & Hers Health by 427.1% during the 4th quarter. Hsbc Holdings PLC now owns 33,582 shares of the company’s stock worth $1,090,000 after purchasing an additional 27,211 shares in the last quarter. Rockefeller Capital Management L.P. lifted its holdings in shares of Hims & Hers Health by 13.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 41,088 shares of the company’s stock valued at $1,334,000 after purchasing an additional 4,980 shares in the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in shares of Hims & Hers Health in the fourth quarter worth $80,000. SHP Wealth Management acquired a new stake in shares of Hims & Hers Health in the fourth quarter worth $106,000. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Hims & Hers Health by 413.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 17,228 shares of the company’s stock valued at $559,000 after buying an additional 13,873 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Major commercial catalyst — HIMS announced availability of a broad suite of Novo Nordisk FDA‑approved GLP‑1 medications for eligible customers, expanding product mix and potential revenue/ARPU upside from higher‑price branded drugs. Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers
• Positive Sentiment: Business model shift — coverage highlights HIMS moving toward a broader mix of branded, FDA‑approved GLP‑1s after the Novo collaboration and FDA shortage resolution, which could lift margins and reduce prior legal/commercial uncertainty. Hims & Hers shifts business model after Novo deal
• Neutral Sentiment: Analyst/features coverage and investor writeups (Seeking Alpha, USA Today sponsored pieces, Yahoo/Fool commentary) are framing a potential reset and longer‑term inflection, useful for context but not immediate proof of sustained upside. Hims & Hers: The Reset Before The Next Inflection
• Neutral Sentiment: Institutional positions remain large (Vanguard, Capital World, Farallon, etc.), which supports liquidity and means any moves could be amplified by institutional flows rather than retail noise. MarketBeat HIMS Coverage
• Negative Sentiment: Fresh analyst pressure — TD Cowen trimmed its price target to $23 and set a “hold”, and other outlets report lower targets/discounted valuations, which can trigger short‑term selling and lower investor conviction. TD Cowen price target cut (Benzinga)
• Negative Sentiment: Legal and governance overhang — a securities‑fraud investigation has been opened (Schall Law Firm), creating regulatory risk that can depress multiples until resolved. Fraud investigation announcement
• Negative Sentiment: Insider selling — CFO Oluyemi Okupe sold ~9.2k shares recently; continued insider sales have been flagged by analysts and can sap market confidence, especially amid valuation compression. SEC Form 4 — Insider Sale

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.